Clinical Trial

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Protocol Amendment History 8 changes
critical Trial completed 2026-07-28
notable Trial sites reduced: 25 -> 22 locations 2026-06-24
notable Enrollment reduced: 66 -> 55 participants 2026-05-29
notable Primary completion moved earlier: 2026-12 -> 2026-06 2026-05-29
minor Completion moved earlier: 2027-01 -> 2026-07 2026-05-29
notable Trial sites reduced: 33 -> 26 locations 2026-04-29
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-03-31
notable Trial sites reduced: 37 -> 33 locations 2026-03-31
Trial Details
NCT Number NCT06395753
Lead Sponsor Debiopharm International SA
Conditions Prostate Cancer
Enrollment 55 participants
Start Date 2024-05-23
Primary Completion 2026-06-24 (estimated)
Study Completion 2026-07-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-27